Expertise in
39
conditions

Dr. Scott H. Okuno

Oncology | Hematology
Mayo Clinic Health System-Southwest Wisconsin Region Inc
700 W Ave S, 
La Crosse, WI 
Accepting New Patients
Offers Telehealth
Expertise in
39
conditions
Mayo Clinic Health System-Southwest Wisconsin Region Inc
700 W Ave S, 
La Crosse, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Scott Okuno is an Oncologist and a Hematologist in La Crosse, Wisconsin. Dr. Okuno is highly rated in 39 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Alveolar Soft Part Sarcoma, and Myxoid Liposarcoma. Dr. Okuno is currently accepting new patients.

His clinical research consists of co-authoring 97 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in WI
Hospital Affiliations
Mayo Clinic Health System-Red Cedar Inc
Mayo Clinic Health System-Franciscan Medical Center Inc
Mayo Clinic Health System Eau Claire Hospital
Mayo Clinic Hlth Systm Franciscan Hlthcare Sparta
Tamarack Health Hayward Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Sanford Health
  • HMO
  • PPO
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS

Locations

MAYO CLINIC HEALTH SYSTEM-SOUTHWEST WISCONSIN REGION INC
700 W Ave S, La Crosse, WI 54601
Other Locations
MAYO CLINIC HEALTH SYSTEM-SOUTHWEST WISCONSIN REGION INC
800 W Ave S, La Crosse, WI 54601
MAYO CLINIC
200 1st St Sw, Rochester, MN 55905
MAYO CLINIC HEALTH SYSTEM-SOUTHWEST WISCONSIN REGION INC
800 E Blackhawk Ave, Prairie Du Chien, WI 53821

Additional Areas of Focus

Dr. Okuno has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Other, Drug
Study Drugs: Pembrolizumab, Pemetrexed, Carboplatin
Study Phase: Phase 2
A Phase II Study of Cabozantinib and Temozolomide in Patients With Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
A Phase II Study of Cabozantinib and Temozolomide in Patients With Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
Enrollment Status: Active_not_recruiting
Publish Date: May 13, 2025
Intervention Type: Other, Drug
Study Drugs: Cabozantinib, Temozolomide
Study Phase: Phase 2
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2025
Intervention Type: Procedure, Biological, Drug
Study Drugs: Atezolizumab, Bevacizumab
Study Phase: Phase 2
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2025
Intervention Type: Other, Drug, Procedure, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 3
A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)
A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drug: MDM2 Inhibitor KRT-232
Study Phase: Phase 1
Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select Sarcomas
Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select Sarcomas
Enrollment Status: Active_not_recruiting
Publish Date: November 21, 2023
Intervention Type: Drug
Study Drugs: Seclidemstat, Cyclophosphamide, Topotecan
Study Phase: Phase 1
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
A Phase 2 Trial of BN-Brachyury and Radiation Therapy in Patients With Advanced Chordoma
A Phase 2 Trial of BN-Brachyury and Radiation Therapy in Patients With Advanced Chordoma
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Biological
Study Drug: BN-Brachyury plus Radiation
Study Phase: Phase 2
Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck or Metastatic Breast Cancer
Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck or Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: February 14, 2023
Intervention Type: Other, Biological
Study Drug: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Study Phase: Phase 1
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: Avapritinib, Regorafenib
Study Phase: Phase 3
A Phase II Study of Pazopanib With Oral Topotecan in Patients With Metastatic and Non-resectable Soft Tissue and Bone Sarcomas
A Phase II Study of Pazopanib With Oral Topotecan in Patients With Metastatic and Non-resectable Soft Tissue and Bone Sarcomas
Enrollment Status: Completed
Publish Date: June 07, 2022
Intervention Type: Drug, Other
Study Drugs: Pazopanib Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Enrollment Status: Completed
Publish Date: April 25, 2022
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
A Phase II Study of Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
A Phase II Study of Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
Enrollment Status: Completed
Publish Date: August 05, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 13 Less Clinical Trials

97 Total Publications

A Phase II Multi-Center Trial of Trabectedin in Combination with Olaparib in Patients with Advanced Unresectable or Metastatic Sarcoma.
A Phase II Multi-Center Trial of Trabectedin in Combination with Olaparib in Patients with Advanced Unresectable or Metastatic Sarcoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 06, 2025
Similar Doctors
Expertise in
29
conditions
Dr. Lori J. Rosenstein
Hematology | Hematology Oncology | Oncology
Expertise in
29
conditions
Dr. Lori J. Rosenstein
Hematology | Hematology Oncology | Oncology

Gundersen Lutheran Medical Center Inc

710 Denton St, 
La Crosse, WI 
 (0.6 mi)
608-782-7300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lori Rosenstein is a Hematologist and a Hematologist Oncology provider in La Crosse, Wisconsin. Dr. Rosenstein is highly rated in 29 conditions, according to our data. Her top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma, Thrombocytopenia, Adult Immune Thrombocytopenia, and Bone Marrow Aspiration. Dr. Rosenstein is currently accepting new patients.

Expertise in
53
conditions
Dr. Eyad M. Al-Hattab
Oncology | Hematology | Hematology Oncology
Expertise in
53
conditions
Dr. Eyad M. Al-Hattab
Oncology | Hematology | Hematology Oncology

Mayo Clinic Health System-Southwest Wisconsin Region Inc

700 W Ave S, 
La Crosse, WI 
 (0.1 mi)
608-785-0940
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Eyad Al-Hattab is an Oncologist and a Hematologist in La Crosse, Wisconsin. Dr. Al-Hattab is highly rated in 53 conditions, according to our data. His top areas of expertise are Familial Colorectal Cancer, Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Colorectal Cancer. Dr. Al-Hattab is currently accepting new patients.

Expertise in
22
conditions
Dr. Wayne A. Bottner
Hematology | Hematology Oncology | Oncology
Expertise in
22
conditions
Dr. Wayne A. Bottner
Hematology | Hematology Oncology | Oncology

Gundersen Lutheran Medical Center Inc

724 Denton St, 
La Crosse, WI 
 (0.6 mi)
608-782-7300
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Wayne Bottner is a Hematologist and a Hematologist Oncology provider in La Crosse, Wisconsin. Dr. Bottner is highly rated in 22 conditions, according to our data. His top areas of expertise are Thrombotic Thrombocytopenic Purpura, Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma, Iron Deficiency Anemia, and Bone Marrow Aspiration. Dr. Bottner is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Okuno's expertise for a condition
ConditionClose
View All 18 Distinguished Conditions
View All 19 Advanced Conditions
View All 114 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile